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Summary
BACKGROUND: Systemic sclerosis is a chronic disabling
disease that is often associated with severe physical and
psychological impairment. Nonetheless, health-related
quality of life (HRQoL) in patients with systemic sclerosis
is often left behind in clinical practice and research. One of
the reasons for this lack of evaluation is the current use of
tools, such as the short form-36 (SF-36) questionnaire, that
are complete but complicated to use in everyday routine.
Other self-reported outcome measures such as the health
assessment questionnaire (HAQ) are simple, but specific-
ally designed for physical disability.
STUDY AIMS AND METHODS: Our aim was to evaluate
the feasibility, acceptability and construct validity of
EQ-5D, a simple and quick self-assessment tool, and to
compare its performance with SF-36 and HAQ. We in-
vestigated 119 consecutive patients with systemic sclerosis
(94% female; age: median 63 years, interquartile range
53–70 years) at three different rheumatology centres. Ac-
ceptability was evaluated from comments made by the pa-
tients and feasibility on the basis of the number of patients
needing assistance or not answering questions (missing
data). Construct validity was based on both convergent
and divergent validity between conceptually similar and
dissimilar domains, respectively, of the compared instru-
ments.
RESULTS: EQ-5D was well accepted by patients. The per-
centage of patients missing data in at least one EQ-5D
domain was 2.5%. Spearman’s correlation coefficients
between similar dimensions of EQ-5D vs SF-36 and vs
HAQ were moderate (≥0.30) to strong (≥0.50); in contrast,
correlation coefficients between less comparable dimen-
sions were weak. As expected, the EQ-5D anxiety/depres-
sion domain did not correlate with any of the HAQ do-
mains. The EQ-5D visual analogue scale (VAS) concord-
ance with SF-36 general health domain and HAQ total
score was strong (≥0.50 for both). Median value for the
EQ-5D index (interquartile range) was 0.81 (0.75–0.86).
The EQ-5D index had correlation coefficients >0.40 with
all SF-36 domains and with all HAQ domains, HAQ total
and HAQ VAS.
CONCLUSIONS: Our data demonstrate good acceptabil-
ity, feasibility and construct validity of EQ-5D in patients
with systemic sclerosis. We suggest the use of EQ-5D in
systemic sclerosis patients as an HRQoL measure in clinic-
al practice, in randomised clinical trials and/or in pharma-
coeconomic evaluations.
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Introduction
Systemic sclerosis is a chronic systemic disease of un-
known aetiology characterised by skin fibrosis, Raynaud’s
phenomenon and variable involvement of the musculo-
skeletal, respiratory, cardiovascular, renal and gastrointest-
inal systems [1]. Patients affected by systemic sclerosis
must cope with a progressive disabling condition often
characterised by pain, disfigurement, feelings of helpless-
ness and impairment in the ability to perform basic activit-
ies [2–4], affecting health-related quality of life (HRQoL)
[5–8]. Furthermore, patients with systemic sclerosis often
also suffer from psychological impairments, such as de-
pression and anxiety, which further impact on their HRQoL
[9, 10].
The assessment of HRQoL is a cornerstone in the manage-
ment of patients with systemic sclerosis [5]. A recent study
of an international cohort demonstrated that patients with
systemic sclerosis may perceive that Raynaud’s phenomen-
on and gastrointestinal involvement have the greatest im-
pact on their HRQoL, differently from physicians, who
consider heart and lung involvement to be the most import-
ant manifestations [6]. Other symptoms, such as pain and
itch [7] or hand disability, should also not be overlooked [4,
11]. The impact of HRQoL on patients affected by systemic
sclerosis is severe and it is surprising how often, in clinic-
al practice, the assessment of HRQoL is neglected in these
patients. One of the reasons could be related to psycho-
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metric or practical limitations of the available instruments.
Patient-reported outcome measures (PROMs) aim to in-
form healthcare professionals and policy decision makers
about the patient’s experience with his/her state attributable
to having / receiving a diagnosis for a disease, the effects
of treatments received, coping with or recovery from the
disease and the related HRQoL [5]. Like many other dis-
eases, systemic sclerosis affects individuals with varying
levels of education, languages, and socioeconomic and cul-
tural backgrounds. Therefore, the use of PROMs in daily
routine should be easy and well accepted, by both patients
and their healthcare professionals. Of course, PROMs have
to be valid and reliable for the target population.
Broadly speaking, among the instruments available for the
assessment of HRQoL we can distinguish generic and
disease-specific types [12, 13]. Generic instruments are ap-
plicable to a wide range of populations defined by age and
sex, type and severity of disease, language, and culture.
Disease-specific instruments have been developed for sev-
eral conditions, with the aim to obtain specific information
on the target condition. However, comparison of HRQoL
is difficult or impossible between different diseases. The
short form-36 (SF-36) [14] and the EQ-5D [15] are among
the most frequently used generic instruments worldwide.
The SF-36 is a very useful self-administered questionnaire
[14]; however, in our experience, completion by the pa-
tients and analysis of the data collected are time-consuming
in clinical practice. EQ-5D is a generic questionnaire inten-
ded to be preference-based, simple and quickly completed,
providing a multi-dimensional description and measure of
health [15]. It can be used to generate a utility index, which
when multiplied by the duration of time corresponding to
a given health state generates quality-adjusted life years
(QALYs). EQ-5D has been widely applied in many non-
rheumatic diseases, as well as in several rheumatic dis-
eases such as rheumatoid arthritis and psoriatic arthrit-
is [16–18]. For economic evaluations, health technology
assessments and decision making especially, the use of
generic preference-based measures has been recommended
by bodies such as the National Institute for Health and
Care excellence (https://www.nice.org.uk/process/pmg9/
chapter/1-foreword). In Italy, national-regional health au-
thorities (DGR n. VIII / 7856 of 30.07.2008) and national
health economic associations have increased their interest
in these measures for the assessment of health technologies
and interventions [19]. However, because the EQ-5D con-
tains only a few questions, it could be considered simplistic
and not capable of fully assessing individuals’ HRQoL.
The health assessment questionnaire (HAQ) is another
widely used questionnaire, which was designed to measure
functional ability or disability in rheumatic diseases [20].
It is quickly completed by the patients; however, by defin-
ition, it does not investigate the psychological aspect of
HRQoL.
Against this background, our specific objectives were to as-
sess the feasibility, acceptability and construct validity of
EQ-5D as compared with SF-36 and HAQ in patients with
systemic sclerosis, in a multicentre study.
Methods
Patients and setting
We recruited consecutive patients referring to out-patient or
in-patient clinics of three rheumatology centres (G. Pini In-
stitute, Ist. Auxologico Italiano and Niguarda Hospital) in
Milan, Italy. The study was approved by the ethics commit-
tee, and informed consent was obtained from all patients.
Patients fulfilled both the 1980 American Rheumatism As-
sociation criteria [21] and the 2013 classification criteria
for systemic sclerosis [22]. The former requires the pres-
ence of a major criterion – skin thickening proximal to
the metacarpophalangeal joints – and two or more of the
following minor criteria: (1) sclerodactyly; (2) digital pit-
ting scars of fingertips or loss of substance of the distal
finger pad; and (3) bilateral basilar pulmonary fibrosis.
The latter consist of eight items (skin thickening of the
fingers of both hands extending proximal to the metacar-
pophalangeal joints, skin thickening of the fingers [either
puffy fingers or sclerodactyly], fingertip lesions [either di-
gital tip ulcers or fingertip pitting scars], teleangiectasia,
abnormal nailfold capillaries, pulmonary arterial hyperten-
sion and/or interstitial lung disease, Raynaud’s phenomen-
on, systemic sclerosis-related autoantibodies (any of anti-
centromere, anti-topoisomerase I/Scl-70, anti-RNA poly-
merase III) and requires a total score ≥9 [22]. Antinuclear
antibodies (ANAs), anti-centromere and anti-
topoisomeraseI-Scl-70 antibodies were tested as described
previously [23]. Pulmonary fibrosis was defined on lung
computed tomography imaging, pulmonary hypertension
from Doppler echocardiography, arrhythmias from 24-hour
electrocardiogram Holter monitoring, and oesophageal in-
volvement from barium X-ray examination.
HRQoL instruments
HRQoL was assessed with three generic instruments –
EQ-5D, SF-36 and HAQ – which were given to the patients
to be self-completed. These questionnaires were chosen for
their ability to assess both physical and psychological com-
ponents of health, and because they are widely used and
recognised for their informative power, allowing comparis-
ons of perceived health within and between different clin-
ical conditions and within the general population.
The EQ-5D is a standardised, self-administered question-
naire that consists of two main parts: the first part generates
a health profile (EQ-5D profile), based on a descriptive
system that defines health in terms of five dimensions:
mobility, self-care, usual activities and pain/discomfort are
related to the physical component of health; the anxiety/
depression domain is related to the mental component of
health. Each dimension has three response categories cor-
responding to “no problem”, “some problems” and “ex-
treme problems / unable to do”. The second part of the
questionnaire consists of a visual analogue scale (EQ-5D
VAS), which measures the overall HRQoL with a score
ranging from 0 (worst imaginable health status) to 100
(best imaginable health state). The health status captured
by EQ-5D refers to the day of completion [24].
The SF-36 questionnaire has demonstrated good validity
and reliability in systemic sclerosis [25, 26] and, together
with the EQ-5D, is considered the gold standard for
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HRQoL assessment in many diseases [27]. It consists of
36 questions and eight domains based on both physical and
emotional components: physical functioning, role-physical
and bodily pain are related more to the physical compon-
ent of health; social functioning, role-emotional and mental
health are related more to the mental component of health;
energy/vitality and general health relate to both compon-
ents. The eight domains can be further grouped into two
summary scores, one specific to physical health (physic-
al component summary score: PCS) and the other to men-
tal health (mental component summary score: MCS) [28,
29]. The questions refer to the previous 4 weeks. The score
for each question is summed and transformed into a 0–100
scale (with 0 and 100 corresponding to the minimum and
maximum levels, respectively, of HRQoL).
The HAQ questionnaire is a self-administered generic in-
strument that measures physical disability in 20 questions
focusing on both upper and lower extremities. The ques-
tions are collapsed into eight domains, all relating to the
physical component of health: dressing/grooming, arising,
eating, walking, hygiene, reaching, gripping and activities.
The results of the eight subscales and the composite disab-
ility score are scored from 0 (no difficulties) to 3 (unable to
do). A visual analogue scale (VAS) for pain is used to as-
sess the presence and severity of pain and consists of a ho-
rizontal VAS that is scored from 0 (no pain) to 100 (severe
pain). The HAQ has a 7 day recall period [20]. It is ex-
tensively used to evaluate disability in systemic sclerosis,
where it has demonstrated good construct validity and re-
liability [5, 25, 30]. Additional information regarding ana-
lysis and scoring of the HAQ instruments is available at ht-
tp://aramis.stanford.edu.
Data analysis
The study sample was described according to the main so-
ciodemographic and clinical characteristics, and HRQoL
data. In particular, the responses obtained with the EQ-5D
profile were converted into a utility index using Italy-spe-
cific social tariffs [31]. Also, the HRQoL of systemic scler-
osis patients was compared with the HRQoL of the general
population based on the results of a recent study assessing
the population reference HRQoL in Italy with use of the
EQ-5D [32]. Because age and sex are recognised to be gen-
erally associated with HRQoL in any population or group
of persons, the results of this comparison were stratified
according to the following age classes (consistent with the
study by Scalone et al. 2015 [32]): 18–35, 36–45, 46–55,
56–65, 66–75 and ≥76 years. As far as sex is concerned, we
compared the HRQoL of patients with systemic sclerosis,
94% of whom were female in this study, with that of the
female general population. HRQoL was reported as the fre-
quency of respondents declaring some or severe problems
in each domain.
All the results were reported as absolute and relative fre-
quency for categorical data, and mean, standard deviation,
median, 25th and 75th percentiles (interquartile range,
IQR) for continuous variables.
Feasibility was measured in terms of the proportion of
patients needing assistance to complete the questionnaire
and the percentage of missing data in at least one domain
per questionnaire. Acceptability was estimated in terms of
patients’ comments on or complaints about the question-
naires.
We examined construct validity of EQ-5D based on a pri-
ori hypotheses for convergent and divergent validity. Con-
vergent validity is related to how strongly conceptually
equivalent domains of different tools correlate with each
other, whereas the opposite is expected between concep-
tually dissimilar domains. Owing to the characteristics of
the variables of the domains, we analysed the correlations
using the nonparametric Spearman-rank correlation coef-
ficients between single and summary domains of EQ-5D
vs SF-36 and EQ-5D vs HAQ. We were interested in in-
vestigating the strength of correlation, if this existed, ac-
cording to the guidelines provided by Cohen et al. [33]:
coefficients from 0.10 to 0.29 were considered low, those
between 0.30 and 0.49 were considered moderate, and cor-
relations of 0.50 or above were considered high.
We identified similar and dissimilar domains and indices
between the EQ-5D and the SF-36, and between the EQ-5D
and the HAQ according to the meaning of each domain
and index reported in their official sources [14, 34]. We hy-
pothesised that the EQ-5D domains relating to the physic-
al component of health (mobility, self-care, usual activities
and pain/discomfort), the VAS and the utility score correl-
ated moderately or highly with the physical domains of the
SF-36 (physical functioning, role-physical, bodily pain and
physical component summary score) and all the domains
of the HAQ. We also hypothesised that the HAQ pain
VAS highly correlated with the pain/discomfort domain
of the EQ-5D. We hypothesised that the anxiety/depres-
sion (EQ-5D) moderately or highly correlated with mental
health, role emotional and the mental component summary
score (SF-36). No correlation was expected between anxi-
ety/depression and any HAQ domain. Vitality and general
health on the SF-36 were expected to correlate moderately
with all the EQ-5D domains, because of their particular
capability to capture both physical and mental compon-
ents of HRQoL. Low correlations were expected between
the other domains not considered conceptually similar. This
approach has been used successfully to analyse the con-
struct validity of the EQ-5D with other standard, widely
used generic HRQoL instruments [35]. In order to simplify
the interpretation of the results, we presented correlation
coefficients for the domains or scales that produced negat-
ive coefficients as positive values due to scores in opposite
directions.
SPSS (version 23, IBM) was used to perform all analyses.
A two-tailed p-value of <0.05 was considered significant.
Results
One hundred and nineteen adult patients with systemic
sclerosis, median age 63 years (IQR 53–70 years), 94.1%
female, were recruited. Median duration of Raynaud’s phe-
nomenon was 10 years (IQR 6–16 years). ANAs were
positive in 98.3% of patients; anti-topoisomeraseI-Scl-70
and anti-centromere antibodies were present in 27.7% and
49.6% of patients, respectively. The demographic and clin-
ical characteristics of the patients are summarised in table
1.
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Detailed HRQoL results are reported in table 2 and in
figures 1 and 2. The total median scores obtained with
the three instruments were 42.5 (PCS) and 48.2 (MCS)
from the SF-36, 60.0 (EQ-VAS) and 0.81 (EQ-utility in-
dex) from the EQ-5D, and 0.5 (total score) and 36.5 (VAS
pain score) from the HAQ.
The patients generally showed reduced levels of HRQoL in
comparison with the general Italian female population [32]
(table 3). In particular, the frequency of patients reporting
some or severe problems in each domain of the EQ-5D pro-
file was higher than the levels reported by the female gen-
eral population in all but one age range: the 18- to 35-year-
old patients apparently had no worse levels of HRQoL than
their counterparts in the general population. However, only
two patients were included in this subgroup; hence we do
not consider this result to be reliable. Nevertheless, the me-
dian and mean VAS and utilities were lower in all the sub-
groups, including the 18- to 35-year-old patients.
Regarding acceptability, we did not receive from the pa-
tients any comment or complaint during or after the com-
pletion of the questionnaires. Regarding feasibility, the per-
centage of patients needing assistance to complete any
HRQoL questionnaire was in total 2.5% (three patients).
Responses were missing in one or more domains in 2.5% of
the EQ-5D, in 7.6% of the HAQ and in 39% of the SF-36
questionnaires.
In the comparison between EQ-5D and SF-36 (table 4),
we found moderate correlation coefficients (0.35–0.48) for
Figure 1
EQ-5D health description.
Figure 2
Health assessment questionnaire (HAQ)health description.
EQ-5D mobility, self-care, pain/discomfort and the SF-36
PCS domain, and low correlation coefficients (0.05–0.21)
between the same domains and the SF-36 MCS domain.
EQ-5D usual activities moderately correlated (0.31) with
MCS and highly correlated (0.71) with PCS. In contrast,
EQ-5D anxiety/depression moderately correlated with
SF-36 MCS (0.44), whereas the correlation coefficient with
PCS was low (0.23). Furthermore, EQ-5D mobility correl-
ated strongly with SF-36 physical functioning (0.63) and
with bodily pain (0.54), weakly with mental health (0.19)
and moderately with the other SF-36 single domains
(0.31–0.41). EQ-5D self-care weakly correlated with
SF-36 mental health, vitality and social functioning
(0.18–0.26) and moderately with the other single SF-36 do-
mains (0.32–0.37). Usual activities correlated moderately
with general health, vitality and mental health (0.45–0.47),
and strongly with the other domains (0.57–0.66). Pain/dis-
comfort correlated strongly with SF-36 bodily pain (0.53)
and weakly to moderately with the other domains
(0.21–0.39). Anxiety/depression correlated strongly with
social functioning and mental health (0.58 and 0.60, re-
spectively), and weakly or moderately with the other single
domains (0.20–0.48). The EQ-5D VAS and utility index,
which measure and value overall health, were moderately
or highly correlated with almost all of the SF-36 single and
composite domains. EQ-VAS only weakly correlated with
social functioning, mental health and MCS (0.27).
In the comparison between EQ-5D and HAQ (table 5),
most of the correlations were moderate to strong between
the EQ-5D mobility, self-care, usual activities, pain/dis-
comfort, VAS and utility and all the HAQ single domains,
the VAS pain and the total score. The highest coefficients
were between self/care and dressing/grooming (0.68), self/
care and HAQ total score (0.71), and HAQ total score and
EQ-5D utility index (0.77). Unexpectedly, we found mod-
erate correlations between HAQ pain VAS and pain/dis-
comfort. Anxiety/depression of the EQ-5D was found to be
weakly correlated with all the HAQ domains (all the coef-
ficients were ≤0.23).
Table 1: Demographic and clinical features of the patients with
systemic sclerosis.
Study population
(n = 119)
Age (years), median (IQR) 63.0 (53.0–70.0)
Female, n (%) 112 (94.1%)
Presence of RP, n (%) 117 (98.3%)
Duration of RP (years), median (IQR) 10.0 (6.0-16.0)
ANA positivity, n (%) 117 (98.3%)
Anti-centromere antibodies, n (%) 59 (49.6%)
Anti-topoisomerase I-Scl-70 antibodies, n
(%)
33 (27.7%)
Pulmonary fibrosis, n (%) 51 (42.9%)
Pulmonary hypertension (%)
PAP (mm Hg), median (IQR)
14 (12%)
27 (25–31)
Arrythmias, n (%) 28 (23%)
Oesophageal involvement, n (%) 78 (65.5%)
Digital ulcers, n (%) 34 (28.6%)
MRSS, median (IQR) 9 (6–14)
ANA = antinuclear antibodies; IQR = interquartile range; MRSS =
modified Rodnan’s skin score; PAP = pulmonary arterial pressure;
RP= Raynaud’s phenomenon.
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Discussion
The results of this study showed that the use of the EQ-5D
is feasible, well accepted and suitable for clinical practice
for the assessment of HRQoL in patients with systemic
sclerosis. The structure of EQ-5D includes both physical
and mental health status, as in the case of SF-36. However,
compared with SF-36, EQ-5D can be completed quickly
and its score can be simply interpreted by physicians.
In this study we found that the domains and indexes of the
EQ-5D generally provided useful information on the gen-
eral health of the patients, including both the physical com-
ponent of health, which affects these patients with several
disabilities and pain, and the mental component of health,
related with the psychological impact attributable to every-
day living with the disease and with the treatment neces-
sary to manage it.
The comparison of the EQ-5D with the more frequently
used SF-36 and HAQ questionnaires is interesting, as the
results showed that all the domains of the latter two ques-
tionnaires were, overall, covered by the EQ-5D. Further-
more, the HAQ, which is a good questionnaire because
it focuses on some specific aspects of daily activities and
physical disability, does not include the mental component
of health, which is a drawback in the assessment of health
in patients with systemic sclerosis, who report comprom-
ised levels of mental health in comparison with the general
population, as confirmed in other studies [9]. The SF-36 is
more complete than the HAQ, but includes 36 questions on
general health, which can be too many for some individu-
als, probably even more so for those who may have seri-
ous difficulties in writing because of typical symptoms af-
fecting the fingers as in the case of patients with systemic
sclerosis. In our study, we found a much lower percentage
of missing data in the EQ-5D than in the HAQ and SF-36.
This difference was probably influenced by the order of
completion: the patients received the EQ-5D first, then the
HAQ and finally the SF-36. However, these results showed
that completion of the EQ-5D is feasible for these patients,
and suggested that many questions or long questionnaires
Table 2: Results for SF-36 domains, EQ-5D and HAQ indices and scales.
Median (IQR)
SF-36:
Physical functioning 65.0 (40.0–90.0)
Role limitations due to physical health 25.0 (0.0–100)
Bodily pain 52.0 (41.0–74.0)
General health 38.5 (25.0–57.0)
Vitality 50.0 (38.8–65.0)
Social functioning 56.3 (50.0–93.8)
Role limitations due to emotional problems 75.0 (0.0–100)
Mental health 62.0 (52.0–76.0)
Physical component summary score 42.5 (30.9–49.3)
Mental component summary score 48.2 (37.7–52.5)
EQ-5D:
VAS 60.0 (50.0–73.8)
Utility index 0.81 (0.75–0.86)
HAQ:
Total score 0.5 (0.0–1.0)
Pain VAS 36.5 (10.0–62.8)
HAQ = health assessment questionnaire; IQR = interquartile range; SF-36: short-form 36; VAS = visual analogue scale
Table 3: Health-related quality of life by age group: comparison of systemic sclerosis patients with the Italian general female population reference data.
Age groups
18–35 years 36–45 years 46–55 years 56–65 years 66–75 years >76 years
EQ-5D domains and
scales
Study
sample
Reference Study
sample
Reference Study
sample
Reference Study
sample
Reference Study
sample
Reference Study
sample
Reference
EQ-5D profile*
Mobility 0% 3.1% 54.5% 3.4% 37.5% 10.8% 43.2% 17.2% 48.6% 27.8% 50% 49.1%
Self-care 50% 1.6% 63.6% 2.2% 37.5% 2.7% 35.1% 2.7% 36.2% 6.6% 30% 14.2%
Usual activities 0% 6.9% 72.7% 6.3% 62.5% 11.8% 48.6% 13.3% 54.3% 21.2% 50% 36.9%
Pain/discomfort 50% 21.1% 90.9% 34.9% 83.3% 50% 83.8% 59.6% 91.4% 69.2% 90% 76.1%
Anxiety/depression 0% 32.8% 45.5% 31% 46.9% 38.4% 62.2% 43.1% 68.6% 43.4% 60% 49.1%
Utility
Mean 0.922 0.944 0.711 0.935 0.824 0.906 0.782 0.889 0.763 0.868 0.745 0.829
Standard deviation 0.109 0.086 0.198 0.078 0.072 0.103 0.163 0.121 0.146 0.115 0.191 0.137
Median 0.922 1.000 0.770 1.000 0.808 0.902 0.808 0.902 0.808 0.869 0.827 0.850
VAS
Mean 70.00 85.0 54.73 82.6 63.31 78.9 63.51 74.7 63.49 70.1 59.00 64.4
Standard deviation 21.21 15.2 20.37 14.9 17.82 17.2 20.29 18.5 16.47 19.8 11.99 23.2
Median 70.00 90.0 50.00 89.5 65.00 80.0 65.00 80.0 60.00 70.0 60.00 70.0
VAS = visual analogue scale
*Frequencies refer to the number of participants reporting some problems summed with the number with severe problems in each domain.
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negatively affected the quantity of data collected and, prob-
ably, their quality. In fact, we can see that the percentage of
missing data was already higher in the HAQ, given second,
and even higher in the SF-36.
We found many correlation coefficients with expected
strength. However, we also found a number of correlations
whose values are different from those expected according
to the official meanings assigned to the domains of each
questionnaire. These results deserve some interpretation
specific for systemic sclerosis. In particular, we found sev-
eral unexpected moderate correlations such as those
between EQ-5D mobility and role emotional, and EQ-5D
anxiety/depression and role physical, and some unexpec-
tedly low correlations such as EQ-5D anxiety/depression
with vitality. These can be explained by the characteristics
of the disease, in which physical and emotional aspects are
peculiarly intertwined: patients with systemic sclerosis of-
ten experience depression due to their physical appearance
(skin thickening of face, hands and arms), or painful phys-
ical complications (digital ulcers), which are also respons-
ible for their limitation in everyday activities, both physic-
al and social [9, 10]. The low correlation between EQ-5D
pain/depression and the SF-36 domain vitality, which is ex-
pected to correlate with both physical and mental compon-
ents of HRQoL, might be also surprising. However, the
vitality domain is very specific and relates to “feeling en-
ergetic and full of pep, or worn out and tired” in SF-36
domain definitions [14]. One possible explanation is that
patients with systemic sclerosis often suffer from lung dis-
ease, which may imply exertional dyspnoea and fatigue.
EQ-5D has been proposed as a measure for HRQoL and
particularly for health utility in clinical trials in systemic
sclerosis [35]. EQ-5D has also been used for HRQoL as-
sessment in patients with primary Reynaud phenomenon
[36]. Finally, EQ-5D is one of the most used tools for the
calculation of QALYs [37].
Several studies in different clinical fields, such as schizo-
phrenia [39], beta-thalassemia major [40] and haemophilia
[41], in which both the EQ-5D and the SF-36 were used
simultaneously, have shown that they provide similar in-
formation about individuals’ health, suggesting that the use
of the EQ-5D as a generic instrument is sufficient and prob-
ably more efficient than the use of a longer generic ques-
tionnaire such as the SF-36. HAQ, which has been de-
signed to be used in a rheumatology setting, seems to be
more specific, since it contains domains related to activities
that can be compromised in subjects with physical disabil-
ities, and hence it can be viewed as a complementary tool.
For instance, reaching, eating and arising in the HAQ are
also contained in three domains of EQ-5D (mobility, self-
care and usual activities), but not at the same level of de-
tail. The domains that we considered conceptually equival-
ent in the EQ-5D and the HAQ correlated with each other,
and those that we considered dissimilar did not correlate: in
Table 4: Correlation coefficients between EQ-5D and SF-36 scores.
EQ-5DSF-36
Mobility Self-care Usual
activities
Pain/
discomfort
Anxiety/
depression
EQ-5D VAS EQ-5D index
Physical function 0.63** 0.37* 0.65** 0.37** 0.20 0.65** 0.64**
Role physical 0.38** 0.33* 0.64** 0.24 0.48** 0.46** 0.64**
Bodily pain 0.54** 0.34* 0.57** 0.53** 0.38** 0.40** 0.69**
General health 0.31* 0.37* 0.46** 0.27 0.26 0.59** 0.54**
Vitality 0.41** 0.23 0.47** 0.23 0.20 0.43** 0.49**
Social function 0.34* 0.26 0.66** 0.39* 0.58** 0.27 0.68**
Role emotional 0.38* 0.32 0.60** 0.35* 0.45** 0.47** 0.65**
Mental health 0.19 0.18 0.45** 0.21 0.60** 0.27 0.58**
SF36 PCS 0.48** 0.43** 0.71** 0.35* 0.23 0.57** 0.68**
SF36 MCS 0.05 0.11 0.31* 0.21 0.44** 0.27 0.44**
MCS = mental component score; PCS = physical component score; VAS = visual analogue scale
** p <0.01; * p <0.05
Positive correlation coefficients are reported also for the domains or scales that, having opposite directions of their scores, produce negative coefficients.
Table 5: Correlation coefficients between EQ-5D and HAQ scores.
EQ-5DHAQ
Mobility Self-care Usual
activities
Pain/
discomfort
Anxiety/
depression
EQ-5D
VAS
EQ-5D index
Dressing/grooming 0.36** 0.68** 0.44** 0.39** 0.10 0.44** 0.64**
Arising 0.24* 0.49** 0.35** 0.30** 0.18 0.35** 0.49**
Eating 0.22* 0.51** 0.42** 0.27** 0.23 0.41** 0.47**
Walking 0.43** 0.32** 0.38** 0.30** 0.15 0.37** 0.50**
Hygiene 0.46** 0.64** 0.44** 0.31** 0.18 0.44** 0.64**
Reaching 0.40** 0.48** 0.51** 0.39** 0.02 0.50** 0.51**
Gripping 0.37** 0.51** 0.40** 0.28** 0.09 0.40** 0.46**
Activities 0.51** 0.52** 0.55** 0.41** 0.07 0.42** 0.64**
HAQ_total 0.46** 0.71** 0.65** 0.57** 0.03 0.57** 0.77**
HAQ_VAS 0.29** 0.30** 0.27** 0.45** 0.04 0.42** 0.41**
HAQ = health assessment questionnaire; VAS = visual analogue scale
** p <0.01, * p <0.05
Positive correlation coefficients are reported also for the domains or scales that, having opposite directions of their scores, produce negative coefficients.
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particular, anxiety/depression in the EQ-5D did not correl-
ate at all with any of the HAQ domains.
The strength of our study is that although EQ-5D has
already been validated in systemic sclerosis [38], to the
best of our knowledge, this is the first study that compares
its performance with the popular HAQ and SF-36.
One limitation of this study is that we did not assess ac-
ceptability with a specific set of questions, and this could
be the subject of a future study. A further limitation is that
we could not compare the feasibility of the EQ-5D with
the other instruments, as we did not arrange the order of
completion in a way that allowed the measurement of this
property. In any case, based on our results we can conclude
that use of the EQ-5D is feasible and that the submission
of many questions to the patients can be counterproduct-
ive in terms of the quantity and, perhaps, the quality of
data provided. Finally, we did not assess other psychomet-
ric properties of the EQ-5D in patients with systemic scler-
osis, such as external reliability and its responsiveness to
real changes in HRQoL.
In conclusion, the results of this study show that the EQ-5D
is a suitable instrument for the routine assessment of
HRQoL in patients with systemic sclerosis, because it is
feasible, well accepted and provides a complete picture of
overall health, despite the reduced number of items (five
domains and one VAS). Furthermore, because it was de-
signed to evaluate health, it also provides a utility index
that can be used for the estimation of the QALY index that
is advised for cost-utility analyses necessary to identify the
most efficient treatment.
EQ-5D, used alone or in combination with HAQ, could be
the most efficient tool, both for the patients with system-
ic sclerosis and their physicians, for the assessment of pa-
tients’ perceived health in clinical routine practice.
In the future, it might be useful to research one or two bolt-
on domains in the EQ-5D, in order to obtain a reduced but
not less informative battery of HRQoL instruments, by re-
ducing those domains (e.g. mobility and walking, self-care
and hygiene) that are probably redundant if the EQ-5D is
used with the HAQ.
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Figure 1
EQ-5D health description.
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Figure 2
Health assessment questionnaire (HAQ)health description.
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